• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.

作者信息

Atwood Scott X, Sarin Kavita Y, Li Jiang R, Yao Catherine Y, Urman Nicole M, Chang Anne Lynn S, Tang Jean Y, Oro Anthony E

机构信息

Department of Dermatology and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California, USA.

Department of Dermatology and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California, USA.

出版信息

J Invest Dermatol. 2015 Aug;135(8):2138-2141. doi: 10.1038/jid.2015.115. Epub 2015 Mar 24.

DOI:10.1038/jid.2015.115
PMID:25801792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4504757/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e9/4504757/cacbf3331de5/nihms674126f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e9/4504757/2e54d682f8c5/nihms674126f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e9/4504757/cacbf3331de5/nihms674126f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e9/4504757/2e54d682f8c5/nihms674126f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e9/4504757/cacbf3331de5/nihms674126f2.jpg

相似文献

1
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.掷出基因骰子：耐药性基底细胞癌中的中性和平滑异常的有害突变
J Invest Dermatol. 2015 Aug;135(8):2138-2141. doi: 10.1038/jid.2015.115. Epub 2015 Mar 24.
2
Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.非经典 hedgehog 信号通路通过 SRF-MKL1 的激活促进基底细胞癌的耐药性。
Nat Med. 2018 Mar;24(3):271-281. doi: 10.1038/nm.4476. Epub 2018 Feb 5.
3
Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.在局部晚期基底细胞癌治疗中，因平滑肌瘤突变导致对Hedgehog信号通路抑制剂维莫德吉产生获得性耐药。
J Am Acad Dermatol. 2014 Nov;71(5):1005-8. doi: 10.1016/j.jaad.2014.08.001. Epub 2014 Sep 4.
4
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.基底细胞癌中 smoothened 抑制剂耐药性的基因组分析
Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001.
5
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.平滑蛋白变体解释了基底细胞癌中大部分的耐药性。
Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002.
6
Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours.皮肤肿瘤中转录因子Gli1的激活与音猬因子信号通路
Nature. 1997 Oct 23;389(6653):876-81. doi: 10.1038/39918.
7
Smoothened mutations underlie Basal cell carcinoma resistance.smoothened 突变是基底细胞癌耐药的基础。
Cancer Discov. 2015 May;5(5):OF9. doi: 10.1158/2159-8290.CD-RW2015-053. Epub 2015 Mar 26.
8
Vismodegib resistance in basal cell carcinoma: not a smooth fit.基底细胞癌中维莫德吉耐药：并非一帆风顺。
Cancer Cell. 2015 Mar 9;27(3):315-6. doi: 10.1016/j.ccell.2015.02.009.
9
Activation of expression of hedgehog target genes in basal cell carcinomas.基底细胞癌中刺猬信号通路靶基因表达的激活
J Invest Dermatol. 2001 May;116(5):739-42. doi: 10.1046/j.1523-1747.2001.01315.x.
10
Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma.人类GLI2和GLI1是基底细胞癌中一种正反馈机制的组成部分。
Oncogene. 2002 Aug 15;21(36):5529-39. doi: 10.1038/sj.onc.1205748.

引用本文的文献

1
Hedgehog pathway, cell cycle, and primary cilium.刺猬信号通路、细胞周期与初级纤毛。
Cell Death Discov. 2025 Jul 3;11(1):302. doi: 10.1038/s41420-025-02605-7.
2
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.小分子抑制剂、免疫检查点抑制剂等：1991 年至 2021 年美国食品和药物管理局批准用于实体瘤的新型治疗药物。
J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9.
3
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma.

本文引用的文献

1
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.平滑蛋白变体解释了基底细胞癌中大部分的耐药性。
Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002.
2
Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma.皮肤鳞状细胞癌中动粒基因KNSTRN的复发性点突变。
Nat Genet. 2014 Oct;46(10):1060-2. doi: 10.1038/ng.3091. Epub 2014 Sep 7.
3
Advanced treatment for basal cell carcinomas.基底细胞癌的先进治疗方法。
在SHH型髓母细胞瘤患者来源的原位异种移植模型中对SMO抑制耐药性的预测建模
Neurooncol Adv. 2022 Mar 13;4(1):vdac026. doi: 10.1093/noajnl/vdac026. eCollection 2022 Jan-Dec.
4
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.Hedgehog 通路抑制剂：急性髓系白血病治疗的新治疗类别。
Blood Cancer Discov. 2020 Aug 11;1(2):134-145. doi: 10.1158/2643-3230.BCD-20-0007. eCollection 2020 Sep.
5
Skin Cancers and the Contribution of Rho GTPase Signaling Networks to Their Progression.皮肤癌以及Rho GTPase信号网络在其进展中的作用。
Cancers (Basel). 2021 Aug 28;13(17):4362. doi: 10.3390/cancers13174362.
6
Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective.紫外线辐射与基底细胞癌：环境视角。
Front Public Health. 2021 Jul 22;9:666528. doi: 10.3389/fpubh.2021.666528. eCollection 2021.
7
Molecular alterations in basal cell carcinoma subtypes.基底细胞癌亚型中的分子改变。
Sci Rep. 2021 Jun 24;11(1):13206. doi: 10.1038/s41598-021-92592-3.
8
Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series.新辅助抗程序性细胞死亡蛋白1疗法用于初治局部晚期基底细胞癌患者：病例系列
JAAD Case Rep. 2020 May 17;6(7):628-633. doi: 10.1016/j.jdcr.2020.05.010. eCollection 2020 Jul.
9
Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties.具有强效抗刺猬信号通路活性及改善类药性质的截短型伊曲康唑类似物
ACS Med Chem Lett. 2019 Aug 23;10(9):1290-1295. doi: 10.1021/acsmedchemlett.9b00188. eCollection 2019 Sep 12.
10
Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.小分子靶向癌蛋白Smo：聚焦新型酰基胍衍生物作为强效Smo抑制剂
Cells. 2018 Dec 14;7(12):272. doi: 10.3390/cells7120272.
Cold Spring Harb Perspect Med. 2014 Jul 1;4(7):a013581. doi: 10.1101/cshperspect.a013581.
4
Identification of recurrent SMO and BRAF mutations in ameloblastomas.成釉细胞瘤中复发性SMO和BRAF突变的鉴定。
Nat Genet. 2014 Jul;46(7):722-5. doi: 10.1038/ng.2986. Epub 2014 May 25.
5
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.SHH 型髓母细胞瘤的基因组测序预测了 smoothened 抑制与基因型相关的反应。
Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
6
Signatures of mutational processes in human cancer.人类癌症中的突变过程特征。
Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14.
7
Mutational landscape of basal cell carcinomas by whole-exome sequencing.全外显子组测序分析基底细胞癌的突变全景。
J Invest Dermatol. 2014 Jan;134(1):213-220. doi: 10.1038/jid.2013.276. Epub 2013 Jun 17.
8
Structure of the human smoothened receptor bound to an antitumour agent.人 smoothened 受体与抗肿瘤剂结合的结构。
Nature. 2013 May 16;497(7449):338-43. doi: 10.1038/nature12167. Epub 2013 May 1.
9
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.在髓母细胞瘤中，平滑肌瘤突变赋予对刺猬信号通路抑制剂的抗性。
Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.